Hydatidiform Mole Clinical Trial
Official title:
A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia
NCT number | NCT00003702 |
Other study ID # | GOG-0174 |
Secondary ID | NCI-2011-02026EC |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | June 1999 |
Verified date | February 2016 |
Source | Gynecologic Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia.
Status | Completed |
Enrollment | 240 |
Est. completion date | |
Est. primary completion date | July 2010 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Histologically proven low-risk gestational trophoblastic neoplasia (persistent hydatidiform mole or choriocarcinoma), defined as 1 of the following: - Less than 10% decrease in the beta human chorionic gonadotropin (HCG) titer over 3 weekly titers - Greater than 20% sustained rise in beta HCG titer over two consecutive weeks - Persistently elevated beta HCG titer more than 4 months after initial curettage (greater than 5 mIU/mL minimum) - Histologically proven nonmetastatic choriocarcinoma - Metastases to vagina, parametria, or lung (if no single pulmonary lesion is greater than 2 cm) - WHO score 0-6 (not including blood group or CT lung) - No histologically confirmed placental site pseudotumor - Must have undergone at least 1 uterine curettage - Previously untreated disease - Performance status - GOG 0-2 - WBC at least 3,000/mm^3 - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGPT and SGOT no greater than 3 times ULN - Alkaline phosphatase no greater than 3 times ULN - No significant prior abnormal hepatic function - Creatinine no greater than 2.0 mg/dL - No significant prior abnormal renal function - Not pregnant or nursing - Fertile patients must use effective contraception during and for one year after study entry - No other prior or concurrent malignancies within the past 5 years except nonmelanomatous skin cancer - No prior chemotherapy for gestational trophoblastic neoplasia - No concurrent curettage except as needed to control vaginal bleeding or to rule out placental site pseudotumor |
Country | Name | City | State |
---|---|---|---|
United States | Gynecologic Oncology Group | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Gynecologic Oncology Group | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay | Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements. | Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months. | |
Primary | Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0 | Number of participants with a maximum grade of 3 or higher during the treatment period. | Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months. | |
Secondary | Number of Patients With a Decline of hCG on Day 1 of Treatment | Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start. | Prior to study entry and on Day 1 of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02892877 -
The French National Reference Centre of GTD
|
N/A | |
Recruiting |
NCT01630954 -
A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole
|
Phase 4 | |
Completed |
NCT01535053 -
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
|
Phase 3 | |
Completed |
NCT00190918 -
A Trial for Patients With Gestational Trophoblastic Disease
|
Phase 2 | |
Recruiting |
NCT03785574 -
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule
|
N/A | |
Completed |
NCT01984099 -
RCT on the Efficacy of Methotrexate for the Prevention of GTD
|
Phase 3 | |
Not yet recruiting |
NCT05637892 -
A Cohort Study of Hydatidiform Mole
|